Is inhaled prophylactic heparin useful for prevention and Management of Pneumonia in ventilated ICU patients?. The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group

Journal of Critical Care

Volumn 34, Issue , 2016, Pages 95-102

  Bandeshe, Hiran ^a,b   Boots, Rob ^a,b   Dulhunty, Joel ^a,b   Dunlop, Rachael ^a,b   Holley, Anthony ^a,b   Jarrett, Paul ^a,b   Gomersall, Charles D ^c   Lipman, Jeff ^a,b   Lo, Thomas ^c   O'Donoghue, Steven ^a,b   Paratz, Jenny ^a,b,d   Paterson, David ^a,b   Roberts, Jason A ^a,b   Starr, Therese ^a,b   Stephens, Di ^e   Stuart, Janine ^a,b   Thomas, Jane ^e   Udy, Andrew ^f   White, Hayden ^g  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d GRIFFITH UNIVERSITY   (Australia)

^e ROYAL DARWIN HOSPITAL   (Australia)

^f The Alfred ^*  (Australia)

^g Intensive Care Unit Logan Hospital   (Australia)

Author keywords

Nebulization; Unfractionated heparin; Ventilator associated complication; Ventilator associated pneumonia

Indexed keywords

HEPARIN; PLACEBO; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL VENTILATOR; MULTICENTER STUDY; NEBULIZATION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VENTILATOR ASSOCIATED PNEUMONIA; ADOLESCENT; AUSTRALIA; CLINICAL TRIAL; INHALATIONAL DRUG ADMINISTRATION; INTENSIVE CARE UNIT; MIDDLE AGED; NEBULIZER; NEW ZEALAND; PNEUMONIA, VENTILATOR-ASSOCIATED; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NEW ZEALAND; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL; YOUNG ADULT;

EID: 84973300498     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2016.04.005     Document Type: Article

References (37)

1. Desai M.H., Mlcak R., Richardson J., et al. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine. J Burn Care Rehabil 1998, 19(3):210-212.
2. Broughton-Head V.J., Shur J., Carroll M.P., et al. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol-Lung C 2007, 293(5):L1240-L1249.
3. Zappala C., Chandan S., George N., et al. The antimicrobial effect of heparin on common respiratory pathogens. Crit Care Resusc 2007, 9(2):157-160.
4. Tyrrell D.J., Horne A.P., Holme K.R., et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999, 46:151-208.
5. Miller A.C., Rivero A., Ziad S., et al. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009, 30(2):249-256.
6. Serisier D.J., Shute J.K., Hockey P.M., et al. Inhaled heparin in cystic fibrosis. Eur Respir J 2006, 27(2):354-358.
7. Lewandowski K., Psuja P., Tokarz A., et al. Anticoagulant activity in the plasma after a single administration of nebulized heparin or LMW heparin fraction (Fraxiparine) in patients undergoing abdominal surgery. Thromb Res 1990, 58(5):525-530.
8. Markart P., Nass R., Ruppert C., et al. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. Aerosol Med Pulm Drug Deliv 2010, 23(3):161-172.
9. Dixon B., Schultz M.J., Smith R., et al. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010, 14:R180.
10. Knaus W.A., Zimmerman J.E., Wagner D.P., et al. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981, 9(8):591-597.
11. McCabe W.R., Jackson G.G. Gram negative bacteremia: I. Etiology and ecology. Arch Intern Med 1962, 110(6):847-855.
12. Neumann F., Lobitz O., Fenk R., et al. The sepsis-related organ failure assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation. Ann Hematol 2008, 87(4):299-304.
13. Qaseem A., Wilt T.J., Weinberger S.E., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155(3):179-191.
14. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Resp Crit Care Med 2001, 163(5):1730-1754.
15. American Thoracic Society Infectious Diseases Society of Americia. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005, 171(4):388-416.
16. Pugin J., Auckenthaler R., Mili N., et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143(5 Pt 1):1121-1129.
17. Bernard G.R., Artigas A., Brigham K.L., et al. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Resp Crit Care Med 1994, 149(3 Pt 1):818-824.
18. Boots R.J., McEvoy J.D., Mowat P., et al. Bronchiolitis obliterans organising pneumonia: a clinical and radiological review. Aust N Z J Med 1995, 25(2):140-145.
19. Boots R., Udy A., Holley A., et al. Preventative strategies for ventilator associated pneumonia. Curr Resp Med Rev 2010, 6(4):238-252.
20. Rea-Neto A., Youssef N.C., Tuche F., et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care 2008, 12(2):R56.
21. Dulhunty J.M., Webb S.A., Paterson D.L., et al. A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. Crit Care Resus 2010, 12(3):162-170.
22. Klompas M., Kleinman K., Platt R., et al. Development of an algorithm for surveillance of ventilator-associated pneumonia with electronic data and comparison of algorithm results with clinician diagnoses. Infect Control Hosp Epidemiol 2008, 29(1):31-37.
23. Hayashi Y., Morisawa K., Klompas M., et al. Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. CID 2013, 56(4):471-477.
24. Vidaur L., Gualis B., Rodriguez A., et al. Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome.[see comment]. Crit Care Med 2005, 33(6):1248-1253.
25. Joshi M., Metzler M., McCarthy M., et al. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006, 100(9):1554-1565.
26. Boots R.J., Lipman J., Bellomo R., et al. The spectrum of practice in the diagnosis and management of pneumonia in patients requiring mechanical ventilation. Australian and New Zealand practice in intensive care (ANZPIC II). Anaesth Intensive Care 2005, 33(1):87-100.
27. Coggon D. Statistics in clinical practice 2003, BMJ, London. 2nd ed.
28. Peat J., Barton B. Medical statistics: a guide to data analysis and critical appraisal 2005, Malden, Mass, Blackwell Pub.
29. Moher D., Schulz K.F., Altman D.G., et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Int Med 2001, 134(8):657-662.
30. Ahmed T., Garrigo J., Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993, 329(2):90-95.
31. Strickland S.L., Rubin B.K., Haas C.F., et al. AARC clinical practice guideline: effectiveness of pharmacologic airway clearance therapies in hospitalized patients. Respir Care 2015, 60(7):1071-1077.
32. Dixon B., Santamaria J.D., Campbell D.J. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008, 12(3):R64.
33. Bendstrup K.E., Gram J., Jensen J.I. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J 2002, 19(4):606-610.
34. Chopra A., Burkey B., Calaman S. A case report of clinically significant coagulopathy associated with aerosolized heparin and acetylcysteine therapy for inhalation injury. Burns 2011, 37(7):e73-e75.
35. Yip L.Y., Lim Y.F., Chan H.N. Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital burns Centre. Burns 2011, 37(7):1154-1160.
36. Cornet A.D., Hofstra J.J., Vlaar A.P., et al. Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats. Shock 2011, 36(4):417-423.
37. Sutton P.P., Gemmell H.G., Innes N., et al. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy. Thorax 1988, 43(1):57-60.